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treatment for all gynaecological patients using CBCT. 
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Purpose/Objective: To analyse 4 field conventional 
radiotherapy (4FRT), intensity modulated radiotherapy (IMRT) 
and volumetric modulated arc therapy (VMAT) in the 
definitive management of cervix cancer and to assess 
whether any dosimetric differences persist with the use of 
larger geometric PTV margins to account for daily variability 
in uterine position. 
Materials and Methods: CT datasets were obtained for 20 
consecutive patients with intact cervix cancer previously 
treated with definitive external beam radiotherapy (with or 
without chemotherapy). The clinical target volume was 
contoured to encompass gross tumour and potential 
microscopic disease including the remaining cervix, uterus, 
upper vagina, parametrium, adnexa and regional lymph 
nodes. The planning target volume (PTV) was generated with 
uterine margins of 1.5cm, 2cm, 2.5cm, 3cm and 4cm used to 
account for internal motion of the uterus, generating five 
PTVs for each patient: PTV1.5, PTV2, PTV2.5, PTV3 and 
PTV4. The rectum, bladder, bowel and femoral heads were 
contoured as organs at risk (OARs). For each patient, a 4FRT 
plan was generated based on conventional field borders 
ensuring coverage of PTV1.5. IMRT and VMAT plans were 
generated for each PTV, except when the PTV extended 
outside 4FRT fields. Prescription dose was 45Gy in 25 
fractions. Plans were evaluated for target coverage, 
conformity, dose homogeneity and dose to OARs. Planning 
time, total monitor units and estimated delivery time were 
also evaluated. 
Results: The median patient age was 56 years (range: 27-84 
years). Stage 1, 2, 3 and 4A disease was seen in 1, 12, 4 and 
3 patients respectively with nodal involvement in 13 patients. 
PTV2.5, PTV3 and PTV4 extended outside the 4FRT fields in 9 
(45%), 13 (65%) and 20 (100%) patients respectively. Target 
coverage was excellent for the 4FRT, IMRT and VMAT plans 
generated, with no significant difference between 
techniques, however, IMRT and VMAT plans were associated 
with a reduction in dose to OARs compared to 4FRT. Mean 
monitor units was lowest with 4FRT, followed by VMAT then 
IMRT.  
Conclusions: IMRT and VMAT are associated with dosimetric 
advantages over 4FRT when margins less than 3cm are used, 
with exceptional target coverage and superior OAR sparing. 
Uterine margins of 3cm or greater commonly resulted in the 
PTV extending outside conventional radiotherapy fields, 
demonstrating no benefit for these advanced planning 
techniques in patients with large variation in uterine 
position. Furthermore, accurate uterine localisation with 
image guidance is critical when considering implementation 
of IMRT or VMAT for cervix cancer treatment. Prospective 
studies are also needed to verify that these newer techniques 
reduce the rates of acute and late toxicities without 
compromising long-term disease control. 
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Purpose/Objective: Evaluate the diagnostic capabilities of 
MRI in the detection of neoplastic lesions of the vagina, as 
well as to optimize the protocol complex MR examination of 
the pelvic organs in clinical use in the planning and 
monitoring of HDR brachytherapy in patients with gynecologic 
cancer with primary or metastatic lesions of the vagina. 
Materials and Methods: With the purpose assess the state of 
the vagina performed 179 MR studies of the pelvic organs in 
108 women with gynecologic cancer, mean age was 58.5 
years. In order to volumetric 3D-planning performed 56 MR 
studies 31 patients with primary and metastatic tumors of 
the vagina treated with brachytherapy in automated complex 
'Microselektron HDR», equipped with isotope 192Ir, using the 
planning system Oncentra Brachy (Nucletron®). Complex MRI 
(Toshiba Vantage Atlas, 1,5 T) pelvic examinations with 
contrast enhancement consisted of native scanning, DWI, 
dynamic contrast enhanced (DCE) examination with 
additional endovaginal MR-compatible applicator 
introduction. All patients previously carried out at different 
times external beam radiotherapy with a total boost dose 46-
60Gr. Re-planning during treatment was performed in 23 
patients. In ultrasonography study to delineate the 
boundaries of the tumor visualized in 62.5% of cases; in CT 
imaging - in 37.5%. For planning we used colpostat diameter 
of 20 mm. 
Results: Neoplastic lesions in vagina were found during 
complex MRI (CMRI) in 58 (51,7%) pts, at lower third - in 5 
(8,6%), as endometrial and vulvar cancer progression, at 
middle third - in 11 (18,9%) pts, at upper third - in 42 
(72,4%), included 18 (31%) pts with vaginal cuff relapse. It 
was revealed as a zone with increasing signal in T2-weighted 
sequence and contrast accumulation in the arterial and 
venous phases. Differential diagnosis with post-radiation 
fibrosis demanded image fusion of T2WI fat sat, DWI and DCE 
with endovaginal MR-suitable applicator, which created 
conditions for better visualization of vaginal wall structure 
and tumor localization because of fold smoothing. In all 
cases, MRI was able to determine the boundaries of the 
tumor process necessary for contouring. At the same time 
25% of patients with symptoms of tumor progression (MRI), 
intimate adhere to vaginal tumors of the bladder or rectum 
involving retro-vesicle, recto-vaginal tissue, demanded 
change of treatment programs, the volume of irradiation, the 
planned total doses, but did not result in rejection of a 
planned rate brachytherapy. According to the dynamic MRI 
performed during the course of radiotherapy, more than 50% 
regression of tumor volume was determined in 50% of 
patients, which in some cases entailed a change in the 
volume of targeted areas.  
Conclusions: CMRI increases the accuracy of primary and 
recurrent vaginal tumors determination and treatment results 
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evaluation and allows clearly define the contours of the 
tumor for planning brachytherapy.  
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Purpose/Objective: Uterine cervical carcinoma is still 
remaining one of the main mortality reasons for female 
population in the developing world. Inspite of widely 
accessible screening and diagnostic procedures in the vast 
majority of cases in our country cervical cancer is revealed in 
locally advanced stages with metastasis in pelvic and 
paraaortal lymph nodes in up to 34% of patients. Concurrent 
chemoradiotherapy is the treatment of choice for cervical 
cancer today but the presence of positive lymph nodes 
require escalation of EBRT dose to these targets. The aim of 
this research was analysis of treatment results of 62 node 
positive cervical cancer patients. 
Materials and Methods: We used the method of integrated 
boost by volumetric arc therapy (VMAT) to increase the EBRT 
dose in target while keeping relatively low doses at the 
organs at risk (bowel, rectum, bladder, femoral heads, pelvic 
bones). Planning was done in automatic regimen and the dose 
distribution was better (more conformal) if two dynamic arcs 
with 15 MV photon beams were used. Number of fractions 
were 25. Fraction dose prescribed to the pelvis (primary 
tumor and regional zone) was 2.0 Gy while to the metastatic 
lymph nodes – 2.3 Gy at the same fraction what makes totally 
50 and 59 Gy respectively (EQD2 by α/β = 10). From the first 
day of treatment patients received concurrently weekly 
cisplatin in dose 40 mg/m2 (max. 70 mg), 5 infusions. After 46 
Gy of EBRT we started HDR brachytherapy which was 
consisted of two weekly 9.0 Gy fractions to HRCTV. 
Results: We analysed close results of the treatment which 
were assessed one month after the course completed. 
Complete regression, partial regression and stabilisation of 
the tumor developed in 83,9% (n=52), 11,3% (n=7), and 4,8% 
(n=3) cases respectively. Early hematological toxicity, 
enteritis, rectitis and cystitis of II – III stages observed in 
42,3%, 15,4%, 11,2% and in 4,3% cases accordingly. 
Conclusions: VMAT EBRT with integrated boost, HDR 
brachytherapy and concurrent cisplatin appears to be safe 
and effective treatment modality for pelvic lymph node 
metastatic uterine cervical carcinoma providing high rate 
local tumor control and acceptable early toxicity. But to do 
final conclusions we need longer follow up period. 
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Purpose/Objective: Treatment of locally advanced cervical 
cancer combines chemotherapy, EBRT and intracavity 
brachytherapy. Differing dose and fractionation schedules 
exist for the use of intracavity brachytherapy in cervical 
carcinoma. Following the switch from MDR to HDR in 2007, 
treatment within our centre was directed by ABS guidelines 
involving 30Gy in 5 fractions until 2010. From 2010 onwards 
due resource availability an altered schedule of 24Gy in 4 
fractions was implemented. We sought to analyse and 
compare outcomes for these two regimens. 
Materials and Methods: A retrospective analysis of treatment 
and outcomes was conducted for patients receiving primary 
chemo radiation for cervical carcinoma between Nov 2007 – 
Feb 2009 and Feb 2010 - Feb 2011. Overall survival and 
recurrence rates were analysed using Kaplan Meier survival 
analysis. Late toxicity was assessed according to 
RTOG/EORTC Late Morbidity Scoring Scheme. 
Results: 123 patients were identified. Patients received 
pelvic EBRT to a dose of 4500cGy in 25 fractions with a 
combination of platinum based induction or concomitant 
chemotherapy schedules followed by intracavity HDR 
brachytherapy. 59 patients received 3000cGy in 5 fractions 
(Group A) and 64 patients received 2400cGy in 4 fractions 
(Group B) of HDR intracavity brachytherapy. Patient 
characteristics were comparable between Group A and B, 
median age 48 (range 24 – 76) and 50 years (range 30 – 88) 
respectively. Squamous cell carcinoma was the most 
commonly observed histological subtype in both groups. Local 
control rates at 3 years are 75% and 81.6% for Group A and B 
respectively. Distant control at 3 years for Group A is 72.5% 
compared to 84.7% in Group B. There was no significant 
difference in PFS between Groups (log rank p = 0.16). OS at 3 
years in Group A was 58% compared to 73% in Group B (log 
rank p = 0.059). The rate of fistula development was 6.8% 
and 4.7% for Group A and B respectively. Late G3 /4 toxicity 
rates in Group A were reported as 10.2% compared with 
6.25% in Group B.  
Conclusions: A reduced dose fractionation schedule to 
2400cGy in 4 fractions is safely deliverable when compared to 
3000cGy in 5 fractions. There is no increase in recurrence or 
late toxicity seen in our patient group. It may be a preferable 
treatment delivery schedule resulting in reduced theatre 
time, reduced number of insertions and anaesthesia 
requirement.  
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Purpose/Objective: Martinez Universal Perineal Interstitial 
Template (MUPIT) is a device designed for the treatment of 
pelvic malignancies or recurrences via perineal. This 
technique allows treating locally advanced gynecological 
tumors, with a better dose coverage than conventional 
intracavitary therapy. Because of the complexity of this 
technique, it is only performed in experienced centers. There 
are few reports of their use in the literature, and with a little 
number of patients in each study. 
